Paper Details

  1. Home
  2. Paper Details

Randomized, double-blinded phase II evaluation of docetaxel with or without doxercalciferol in patients with metastatic, androgen-independent prostate cancer.

Author: AhujaHarish, AlbertiDona, AttiaSteven, BlankJules, EastmanMichael, EickhoffJens, GlodeMichael, HorvathDottie, JumonvilleAlcee, LiuGlenn, MarnochaRebecca, McNeelDouglas, ShevrinDaniel, StaabMary Jane, StrausJane, WildingGeorge

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Doxercalciferol did not improve PSA response rate or survival when combined with docetaxel in men with androgen-independent prostate cancer. Toxicity was similar in both groups.
Paper Details　
Original Abstract of the Article :
PURPOSE: Docetaxel is standard of care for androgen-independent prostate cancer (AIPC). Doxercalciferol (1 alpha-hydroxyvitamin D2) had modest activity in phase I/II trials. Preclinical data support combining vitamin D analogues with docetaxel to treat AIPC. EXPERIMENTAL DESIGN: Chemotherapy-naive ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/18413835

データ提供：米国国立医学図書館（NLM）

Androgen-Independent Prostate Cancer: Seeking New Treatment Strategies

Prostate cancer is a significant health concern for men. Androgen-independent prostate cancer (AIPC) is a particularly challenging form of the disease, often resistant to traditional therapies. This research examines the effectiveness of combining docetaxel, a standard treatment for AIPC, with doxercalciferol, a vitamin D analogue.

Doxercalciferol: A Disappointing Outcome

The study randomized chemotherapy-naive men with metastatic AIPC to receive docetaxel with or without doxercalciferol. The primary endpoint was prostate-specific antigen (PSA) response, and secondary endpoints included progression-free survival, overall survival, objective response, and toxicity. Disappointingly, the results showed no significant improvement in PSA response, progression-free survival, overall survival, or objective response in the doxercalciferol group compared to the placebo group. Toxicity was similar between the groups.

Health Implications and Everyday Applications

This study provides valuable information for healthcare professionals treating AIPC patients. While doxercalciferol did not show significant benefit in combination with docetaxel, other vitamin D analogues are still under investigation. It’s crucial to stay informed about the latest research and discuss treatment options with a qualified oncologist. Like a camel navigating a vast and sometimes challenging desert, it’s essential to seek expert guidance when managing complex health conditions.

Dr.Camel's Conclusion

This study suggests that doxercalciferol, a vitamin D analogue, does not enhance the effectiveness of docetaxel in treating AIPC. While disappointing, this research reinforces the need for continued exploration of new treatment strategies for this challenging disease. It’s essential to consult with an oncologist to discuss the most appropriate treatment options. Like a camel adapting to the changing sands of the desert, we must remain persistent in our search for effective treatments for AIPC.

Date :
  1. Date Completed 2008-05-21
  2. Date Revised 2021-10-20
Further Info :

Pubmed ID

18413835

DOI: Digital Object Identifier

NIHMS907922

Related Literature

Article Analysis
・Effects of doxercalciferol
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.